CO5601030A2 - Derivados de quinolinona/benzoxazinona y usos de los mismos - Google Patents

Derivados de quinolinona/benzoxazinona y usos de los mismos

Info

Publication number
CO5601030A2
CO5601030A2 CO05085018A CO05085018A CO5601030A2 CO 5601030 A2 CO5601030 A2 CO 5601030A2 CO 05085018 A CO05085018 A CO 05085018A CO 05085018 A CO05085018 A CO 05085018A CO 5601030 A2 CO5601030 A2 CO 5601030A2
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
nrcrd
independently
quinolinona
Prior art date
Application number
CO05085018A
Other languages
English (en)
Inventor
Ralph New Harris Iii
David Bruce Repke
Russell Stephen Stabler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5601030A2 publication Critical patent/CO5601030A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula: y sales farmacéuticamente aceptables o profármacos (prodrugs) de los mismos,en la que:m es un número de 0 a 4;p es un número de 1 a 3;q es un número de 1 a 3;r es un número de 1 a 3;A es arileno eventualmente sustituido o heteroarileno eventualmente sustituido;E es N o C;X es O, S, o -CRaRb- en la que Ra y Rb con independencia entre sí son hidrógeno o alquilo;cada R1 con independencia de su aparición es halo, alquilo, haloalquilo, heteroalquilo, hidroxi, nitro, alcoxi, ciano, -S(O)sRc, -NRcRd, -C(=O)-NRcRd, -SO2-NRcRd-N(Rc-C(=O)-Rd o -C(=O)-Rc, en la que s es un número de 0 a 2 y Rc y Rd con independencia entre sí son hidrógeno o alquilo;Y es -(CR2R3)n- en la que n es 1 ó 2 y R2 y R3 con independencia entre sí son hidrógeno o alquilo, o X e Y, juntos, forman un grupo alquenileno;R4, R5, R6, R7, R8, y R9 con independencia entre sí son hidrógeno o alquilo; y R10 es hidrógeno, alquilo, arilalquilo, ariloxialquilo, heteroarilo o heterociclilo.
CO05085018A 2003-03-11 2005-08-25 Derivados de quinolinona/benzoxazinona y usos de los mismos CO5601030A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357403P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
CO5601030A2 true CO5601030A2 (es) 2006-01-31

Family

ID=32990787

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05085018A CO5601030A2 (es) 2003-03-11 2005-08-25 Derivados de quinolinona/benzoxazinona y usos de los mismos

Country Status (23)

Country Link
US (2) US6943169B2 (es)
EP (1) EP1603880B1 (es)
JP (1) JP4404893B2 (es)
KR (1) KR100691090B1 (es)
CN (1) CN100455570C (es)
AR (1) AR043510A1 (es)
AT (1) ATE394377T1 (es)
AU (1) AU2004220388B9 (es)
BR (1) BRPI0408204A (es)
CA (1) CA2518403A1 (es)
CL (1) CL2004000450A1 (es)
CO (1) CO5601030A2 (es)
DE (1) DE602004013560D1 (es)
ES (1) ES2305742T3 (es)
HR (1) HRP20050775A2 (es)
MX (1) MXPA05009523A (es)
MY (1) MY135470A (es)
NO (1) NO20054135L (es)
NZ (1) NZ541642A (es)
RU (1) RU2333204C2 (es)
TW (1) TWI289141B (es)
WO (1) WO2004080969A1 (es)
ZA (1) ZA200506831B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
AU2004261582C1 (en) 2003-07-22 2010-01-07 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US7592457B2 (en) * 2004-10-20 2009-09-22 Korea Research Institute Of Chemical Technology 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
JP2010533187A (ja) * 2007-07-11 2010-10-21 ダウ・コーニング・コーポレイション 薬物を送達するための組成物
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114085179B (zh) * 2021-11-29 2024-05-03 福建科宏生物工程股份有限公司 一种n-乙酰基-5-甲氧基色胺的制备方法
WO2023192430A1 (en) * 2022-03-30 2023-10-05 University Of Florida Research Foundation, Incorported Compounds for treating psychostimulant misuse

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733321A (en) * 1971-07-06 1973-05-15 Squibb & Sons Inc 1,4-benzothiazin-3-ones
US4078062A (en) * 1976-10-28 1978-03-07 E. R. Squibb & Sons, Inc. Substituted 2H-1,4-benzothiazin-3(4H)-ones
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
NZ501258A (en) * 1997-07-11 2001-07-27 Smithkline Beecham P Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression
WO1999050254A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
WO1999050263A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
BR9815784A (pt) 1998-03-31 2000-11-21 Warner Lambert Co Benzoxazinonas/benzotiazinonas como inibidores de protease de serina
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
AU2001236606A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
WO2001057019A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
ATE337780T1 (de) * 2000-11-24 2006-09-15 Smithkline Beecham Plc Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
CN1254469C (zh) * 2001-08-10 2006-05-03 弗·哈夫曼-拉罗切有限公司 具有5-ht6受体亲和性的芳基磺酰基衍生物
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds

Also Published As

Publication number Publication date
CA2518403A1 (en) 2004-09-23
BRPI0408204A (pt) 2006-02-14
MY135470A (en) 2008-04-30
WO2004080969A1 (en) 2004-09-23
EP1603880B1 (en) 2008-05-07
MXPA05009523A (es) 2005-10-18
JP4404893B2 (ja) 2010-01-27
ES2305742T3 (es) 2008-11-01
AU2004220388B2 (en) 2009-12-10
JP2006515344A (ja) 2006-05-25
KR100691090B1 (ko) 2007-03-12
DE602004013560D1 (de) 2008-06-19
CL2004000450A1 (es) 2005-01-07
AU2004220388A1 (en) 2004-09-23
NO20054135L (no) 2005-09-23
ATE394377T1 (de) 2008-05-15
ZA200506831B (en) 2006-06-28
KR20050109078A (ko) 2005-11-17
CN100455570C (zh) 2009-01-28
RU2333204C2 (ru) 2008-09-10
HRP20050775A2 (en) 2006-10-31
TWI289141B (en) 2007-11-01
US20050261308A1 (en) 2005-11-24
NZ541642A (en) 2008-03-28
NO20054135D0 (no) 2005-09-06
AR043510A1 (es) 2005-08-03
EP1603880A1 (en) 2005-12-14
US7476675B2 (en) 2009-01-13
AU2004220388B9 (en) 2010-01-07
US6943169B2 (en) 2005-09-13
US20040186092A1 (en) 2004-09-23
CN1759101A (zh) 2006-04-12
TW200424189A (en) 2004-11-16
RU2005131172A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
CO5601030A2 (es) Derivados de quinolinona/benzoxazinona y usos de los mismos
AR043436A1 (es) Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
RS50980B (sr) Derivati n-hidroksiamida i njihova upotreba
DK1781683T3 (da) Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
AR052915A1 (es) Derivados de pirrolidin y piperidin acetileno
TW200745058A (en) MMP-13 selective inhibitors
AR049401A1 (es) Aza-biciclononanos
NI201000018A (es) Derivado de oxopirazina y herbicida
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
RS50537B (sr) Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii
ES2192520T3 (es) Composicion farmaceutica.
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
NO20052976L (no) Fosfodiesterase-4-inhibitorer.
TW200612920A (en) Novel imidazolidine derivatives
RS54047B1 (en) PROCEDURE FOR OBTAINING 4-OXOCHINOLINE COMPOUNDS
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
HRP20080243T3 (en) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
AR040133A1 (es) Derivados de n-acilamino bencil eter
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
AR046753A1 (es) Derivados de benzoxazina y usos de los mismos
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism

Legal Events

Date Code Title Description
FC Application refused